Acadia Pharmaceuticals Inc. develops and commercializes therapies for neurological and rare diseases. Its commercial portfolio includes NUPLAZID (pimavanserin) for hallucinations and delusions associated with Parkinson’s disease psychosis and DAYBUE (trofinetide), including DAYBUE STIX, for Rett syndrome.
Company news commonly covers product revenue from NUPLAZID and DAYBUE, formulation and launch updates for trofinetide, clinical and scientific presentations across neurological disorders, pipeline work in Alzheimer’s disease psychosis, Lewy body dementia psychosis and essential tremor, investor-conference participation, and board or research-and-development leadership changes.
Acadia Pharmaceuticals (NASDAQ:ACAD) hosted its inaugural R&D Day to showcase its pipeline programs and growth strategy. The company plans to initiate seven Phase 2 or Phase 3 studies during 2025-2026, with five key readouts anticipated by 2027.
Key pipeline highlights include ACP-101 for Prader-Willi syndrome, ACP-204 for Alzheimer's and Lewy Body Dementia Psychosis, ACP-211 for major depressive disorder, ACP-711 for Essential Tremor, and ACP-271 for Tardive Dyskinesia and Huntington's Disease. The company's commercial franchises are expected to generate over $1 billion in net sales this year.
Acadia Pharmaceuticals (NASDAQ: ACAD) announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference, scheduled for June 9, 2025, at 4:00 p.m. Eastern Time. The company will engage in a fireside chat that will be webcast live on Acadia.com's investor section, with the recording available for approximately one month afterward.
Acadia is a neuroscience-focused pharmaceutical company known for developing the first FDA-approved treatment for Parkinson's disease psychosis-related hallucinations and delusions, as well as the first approved drug for Rett syndrome in the US and Canada. The company's current clinical-stage pipeline includes programs targeting Prader-Willi syndrome, Alzheimer's disease psychosis, and various other neuroscience and neuro-rare diseases.
Acadia Pharmaceuticals (NASDAQ: ACAD) has appointed Allyson McMillan-Youngblood as Senior Vice President of their Rare Disease Franchise. In her new role, she will focus on maximizing the potential of DAYBUE® and preparing for future product launches in the company's rare disease portfolio. McMillan-Youngblood brings over 20 years of pharmaceutical industry experience, most recently serving as Senior Vice President and Business Unit Head of U.S. Oncology at Bristol Myers Squibb, where she led two major acquisitions in rare tumors. Her extensive background includes roles at Pfizer and BMS across various therapeutic areas including oncology, immunology, CNS, and cardiovascular disorders.
Acadia Pharmaceuticals (NASDAQ: ACAD) has granted inducement awards to 28 new employees under its 2024 Inducement Plan, as approved by the Compensation Committee. The awards include 64,252 non-qualified stock options with an exercise price of $14.81 per share and 56,277 restricted stock units (RSUs).
The stock options will vest over four years, with 25% vesting after one year and the remainder monthly over 36 months. The RSUs will vest over four years, with 50% vesting after two years and the remaining 50% in two equal annual installments. Both awards are subject to continued employment.
Acadia is a neuroscience company known for developing the first FDA-approved treatment for Parkinson's disease psychosis and Rett syndrome in the US and Canada. Their pipeline includes programs for Prader-Willi syndrome and Alzheimer's disease psychosis.
Acadia Pharmaceuticals (NASDAQ: ACAD) reported strong Q1 2025 financial results with total revenues of $244.3 million, up 19% year-over-year. The company's two key products showed significant growth: NUPLAZID net sales reached $159.7 million (+23% YoY) and DAYBUE achieved $84.6 million (+11% YoY). DAYBUE reached a record of 954 unique patients, and the company expanded its field force by 30%. Acadia maintained its 2025 guidance with total revenues of $1.03-$1.095 billion, while increasing R&D expense guidance to $330-$350 million due to accelerated timeline for the ACP-101 Phase 3 study in Prader Willi Syndrome, now expected in early Q4 2025.
The company reported Q1 net income of $19.0 million ($0.11 per share) compared to $16.6 million ($0.10 per share) in Q4 2024. Cash position stood at $681.6 million as of March 31, 2025.
Acadia Pharmaceuticals (NASDAQ: ACAD) announced its participation in a fireside chat at the BofA Securities 2025 Health Care Conference on May 13, 2025, at 3:40 p.m. Pacific Time. The presentation will be available via webcast on the company's website and archived for approximately one month.
Acadia is a neuroscience-focused pharmaceutical company that has developed the first FDA-approved treatment for Parkinson's disease psychosis-related hallucinations and delusions, as well as the first approved drug for Rett syndrome in the US and Canada. The company's pipeline includes clinical-stage programs targeting Prader-Willi syndrome, Alzheimer's disease psychosis, and other neuroscience and neuro-rare diseases.